vaccines available to prevent astrovirus infection, however antibodies developed by 23 healthy individuals during previous infection correlate with protection from 24 reinfection, suggesting that an effective vaccine could be developed. In this study, 25 we investigated the molecular mechanism by which several strains of human 26 astrovirus serotype 2 (HAstV-2) are resistant to the potent HAstV-2-neutralizing 27 monoclonal antibody PL-2 (mAb PL-2). Sequencing of the HAstV-2 capsid genes 28 reveals mutations in the PL-2 epitope within the capsid's spike domain. To 29 understand the molecular basis for resistance from mAb PL-2 neutralization, we 30 determined the 1.35 Å-resolution crystal structure of the capsid spike from one of 31 these HAstV-2 strains. Our structure reveals a dramatic conformational change in a 32 loop within the PL-2 epitope due to a serine-to-proline mutation, locking the loop in 33 a conformation that sterically blocks binding and neutralization by mAb PL-2. We 34
show that mutation to serine permits loop flexibility and recovers mAb PL-2 binding. 35 Importantly, we find that HAstV-2 capsid spike containing a serine in this loop is 36 immunogenic and elicits antibodies that neutralize all HAstV-2 strains. Taken 37 together, our results have broad implications for rational selection of vaccine strains 38 that do not contain prolines in antigenic loops, so as to elicit antibodies against 39 diverse loop conformations. 40 3 IMPORTANCE 41
Human astroviruses (HAstVs) infect nearly every person in the world during 42 childhood and cause diarrhea, vomiting, and fever. In this study, we investigated 43 how several strains of HAstV are resistant to a virus-neutralizing monoclonal 44 antibody. We determined the crystal structure of the capsid protein spike domain 45 from one of these HAstV strains and found that a single amino acid mutation induces 46 a structural change in a loop that is responsible for antibody binding. Our findings 47 reveal how viruses can escape antibody neutralization and provide insight for the 48 rational design of vaccines to elicit diverse antibodies that provide broader 49 protection from infection. 50
INTRODUCTION 51
Astroviruses are a diverse family of small, non-enveloped, icosahedral 52 positive-sense RNA viruses that infect a wide range of mammalian and avian 53 species (1) . In poultry, astroviruses have been associated with a large variety of 54 disease manifestations, growth defects, and mortality(2). In humans, astroviruses 55 are a leading cause of viral diarrhea in children, immunocompromised individuals, 56 and the elderly (1, (3) (4) (5) , accounting for 2 to 9% of all acute nonbacterial 57 gastroenteritis in children worldwide (6). Human astroviruses (HAstVs) have also 58 been associated with systemic infections and neurological complications such as 59 encephalitis(7-9). There are three distinct phylogenetic clades of HAstV: canonical 60 genotypes (HAstV-1-8) and noncanonical genotypes MLB1-3 and VA1-5(6, 10, 11). 61
HAstV-1 is the most prevalent serotype worldwide(3, 12), while prevalence of 62
HAstV-2, the subject of the present study, can vary widely (13) . 63
Several studies demonstrate that the adaptive immune response plays a key 64 role in controlling astrovirus infection and disease. Approximately 75% of people in 65 the United States have developed antibodies against HastV by the age of ten (14), 66
indicating that an adaptive immune response is mounted in humans. Clinical studies 67 of healthy adult volunteers infected with HAstV revealed that those that had anti-68 HAstV antibodies experienced little or no disease, whereas those that did not have 69 anti-HAstV antibodies experienced more severe diarrheal disease (15, 16) . In 70 another study, immunoglobulin therapy led to the recovery of an 71 immunocompromised patient with a severe and persistent HAstV infection (17) . 72
More recently, astrovirus infectivity was tested in rag1 knockout mice (Rag1 -/ -), 73 5 which lack mature B cells or T cells. These studies show that Rag1 -/mice infected 74 with murine astrovirus had higher (2 logs) levels of viral RNA compared to wild-75 type mice (18) . Altogether, these studies support that adaptive immunity is key to 76 the control of astrovirus infection. Furthermore, these studies suggest that a vaccine 77 and therapeutic antibodies could be developed to prevent and/or treat HAstV 78 infections. 79
Understanding the sites at which antibodies bind HAstV and understanding 80 how the virus might resist antibody neutralization can inform the development of 81 vaccines and antiviral therapeutics. Mature HAstV particles are comprised of a small 82 RNA genome surrounded by a ~35nm T=3 icosahedral capsid protein shell 83 projecting 30 knob-like spikes(19). Our lab and others have recently determined the 84 crystal structure of the HAstV capsid core domain, which forms the icosahedral shell 85 that encapsulates the viral RNA genome(20, 21). Our lab and others have also 86 determined the crystal structure of the HAstV capsid spike domain, which forms the 87 dimeric spike protrusions on the virus surface (20, 22, 23) . While both the HAstV 88 capsid core and spike domains are antigenic, the spike domain is ~5-fold more 89 antigenic(20). In addition, the capsid spike fragment binds all four of the previously 90 described HAstV-neutralizing monoclonal antibodies (mAbs), including mAb PL-2 91 that neutralizes serotype 25) . 92
We recently engineered the single chain variable fragment (scFv) of the PL-2 93 antibody and used X-ray crystallography to determine the structure of the HAstV 94 capsid spike / scFv PL-2 complex (23, 26) . We found that the HAstV-2 capsid spike's 95 loop 1 plays a major role in antibody PL-2 binding. We also provided evidence that 96 6 the HAstV capsid spike is a receptor-binding domain and that antibody PL-2 blocks 97 spike binding to human cells (23) . 98
In the present study, we investigated the molecular mechanism by which 99 several strains of HAstV-2 are resistant to neutralization by mAb PL-2. We find that 100 a single point mutation in the capsid spike loop 1 of these HAstV-2 strains is 101 responsible for resistance to antibody neutralization. Structural studies reveal how 102 this mutation prevents antibody binding. Altogether, these studies have broad 103 implications for rational design of vaccines and therapeutic antibodies. 104
105

RESULTS 106
HAstV-2 strain resistance to antibody PL-2 neutralization. Monoclonal antibody 107 PL-2 (mAb PL-2) was reported to neutralize infectivity of HAstV-2 strain CDC-Spain 108 (HAstV-2-CDC-Spain), and our recent structural and functional studies suggested 109 that mAb PL-2 may neutralize HAstV-2 by blocking a receptor-binding site on the 110 capsid surface (23, 24) . With the intention to directly investigate the mechanism of 111 mAb PL-2 neutralization, we began our studies by aiming to confirm that mAb PL-2 112 neutralizes HAstV-2 infection in cell culture. HAstV-2 strain Oxford (HAstV-2-113
Oxford) was pre-incubated with increasing concentrations of mAb PL-2 or scFv PL-2 114 and then added to Caco-2 cells. To our surprise, no neutralization was observed by 115 either mAb PL-2 or scFv PL-2 ( Fig. 1A,B ). Similar results were observed with three 116
other HAstV-2 strains tested (HAstV-2-RIVMa, -RIVMb, and -RIVMc). In comparison, 117 complete neutralization of HAstV-2-Oxford was obtained with polyclonal antibodies 118 raised against HAstV-2-Oxford virus, and even partial neutralization was obtained 7 with polyclonal antibodies raised against HAstV-8-Yuc8 (Fig. 1C ). Unfortunately, 120
HAstV-2-CDC-Spain, which was originally used to produce mAb PL-2, was no longer 121 available in the several labs that we queried. 122 123 Sequence of HAstV-2 strains. We used RT-PCR to determine the sequence of the 124 capsid spike from each of the four HAstV-2 strains (strains Oxford, RIVMa, RIVMb, 125 and RIVMc). We then aligned these sequences to the reported capsid protein 126 sequence of HAstV-2-CDC-Spain ( Fig. 1E ). Focusing on the amino acids within the 127 mAb PL-2 epitope, we observed two amino acids that are mutated in all four HAstV-128 2 strains: Ser463Pro and Glu580Lys. Ser463 falls in the middle of the PL-2 epitope 129 in loop 1 of the capsid spike domain whereas Glu580 resides at the edge of the 130 epitope(23). 131 132 Structure of Spike-2-Oxford. To understand the molecular basis for resistance to 133 mAb PL-2 neutralization, we expressed and purified recombinant HAstV-2-Oxford 134 capsid spike domain (Spike-2-Oxford) and observed that it elutes as a dimer by size 135 exclusion chromatography, consistent with previous observations for recombinant 136
HAstV-2 capsid spike domain (Spike-2-CDC-Spain)( Fig. 2A )(23). We used an 137 enzyme-linked immunosorbent assay (ELISA) to test if mAb PL-2 binds Spike-2-138
Oxford. Consistent with the lack of mAb PL-2 neutralization of HAstV-2-Oxford 139 infectivity, we observed no binding of mAb PL-2 to Spike-2-Oxford, whereas dose-140 dependent binding was observed for Spike-2-CDC-Spain (Fig. 2B ). We then 141 crystallized Spike-2-Oxford and solved its structure to 1.35 Å resolution (Fig. 2C,  142 8 Table 1 ). The overall structure of Spike-2-Oxford is very similar to that of Spike-2-143 CDC-Spain, with an RMSD of 0.315 Å. 144
The major structural difference between Spike-2-Oxford and Spike-2-CDC-145
Spain occurs in loop 1, which interacts with antibody PL-2 ( Fig. 3 ). We observe that 146 the Ser463Pro mutation in loop 1 leads to the formation of a short alpha helix, 147 locking loop 1 into a distinct conformation. Loop 1 adopts this same "down" 148 conformation in all four molecules of Spike-2-Oxford in the crystallographic 149 asymmetric unit (Fig. 3A) . In contrast, loop 1 in Spike-2-CDC-Spain appears more 150 flexible and adopts different conformations in each of the four molecules in the 151 crystallographic asymmetric unit, with two molecules in a "down" conformation, 152 one molecule in an intermediate conformation, and one molecule in an "up" 153 conformation ( Fig. 3B ). Thus, it appears that the flexibility of loop 1 in Spike-2-CDC-154
Spain may be required for binding of antibody PL-2. Indeed, we observed that loop 1 155 adopts a single "up" conformation in all eight molecules of Spike-2-CDC-Spain/scFv 156 PL-2 complex in the crystallographic asymmetric unit (Fig. 3C) . Superposition of the 157 Spike-2-Oxford structure onto the structure of the Spike-2-CDC-Spain/scFv PL-2 158 complex reveals how the "down" conformation of loop 1 in Spike-2-Oxford would 159 sterically clash with antibody heavy chain CDR 3 (Fig. 4) . Overall, our structural 160 studies suggest that the Ser463Pro mutation locks loop 1 into a rigid conformation 161 that clashes with and completely prevents antibody PL-2 binding. 162 163 Spike-2-Oxford mutant Pro463Ser restores binding to mAb PL-2. Our structural 164 studies lead to the hypothesis that HAstV-2-Oxford capsid Pro463 is responsible for 165 9 the lack of binding and neutralization by mAb PL-2. To test our hypothesis, we 166 expressed and purified recombinant Spike-2-Oxford Pro463Ser mutant and 167 observed that it is pure and elutes as a dimer by size exclusion chromatography ( Fig.  168 5A and 5B). We then performed an ELISA using purified mAb PL-2 and scFv PL-2 169 ( Fig. 5B-D) . We observed that both antibody PL-2 samples now bind to Oxford Pro463Ser mutant at similar levels as binding to Spike-2-CDC-Spain. These 171 results confirm that a single amino acid in the capsid protein of HAstV-2-Oxford is 172 responsible for resistance to binding and neutralization by mAb PL-2. 173 174 Spike-2-CDC-Spain elicits HAstV-2 cross-neutralizing antibodies. We 175 hypothesized that Spike-2-CDC-Spain, which contains Ser463 in loop 1, would elicit 176 antibodies against diverse conformations of loop 1 that can neutralize the infectivity 177 of all four HAstV-2 strains. To test this, we immunized rabbits with purified, 178 recombinant Spike-2-CDC-Spain and found that the anti-Spike-2-CDC-Spain 179 polyclonal antibodies effectively neutralized all four strains of HAstV-2 in a 180 concentration-dependent manner (Fig. 1D ). Although the spike most likely contains 181 more than one neutralizing epitope, this study does show that the Spike-2-CDC-182
Spain, which contains Ser463, is able to elicit antibodies that neutralize HAstV-2 183 strains containing Pro463. Moreover, this is the first demonstration that 184 recombinant HAstV capsid spike can elicit HAstV-neutralizing antibodies and may 185 be an effective immunogen in a HAstV subunit vaccine. 186
187
DISCUSSION
10
Here, we investigated the molecular mechanism by which four strains of HAstV-2 189 (HAstV-2-Oxford, -RIVMa, -RIVMb, and -RIVMc) are resistant to the HAstV-2- Spain-neutralizing monoclonal antibody PL-2. Serotype HAstV-2 has been reported 191 to have especially high genetic heterogeneity between strains(13). We describe the 192 crystal structure of Spike-2-Oxford and find that Pro463 induces a rigid helix in loop 193 1, locking it in a "down" conformation that sterically clashes and prevents binding 194 by mAb PL-2. We further show that the point mutant Pro463Ser recovers binding by 195 mAb PL-2. Finally, we show that recombinant Spike-2-CDC-Spain is immunogenic 196 and elicits antibodies that neutralize all four HAstV-2 strains. 197
Viruses constantly evolve under the pressure of a host's immune system, and 198 one of the most efficient ways to evade immunity is by acquiring mutations that 199 sterically clash with antibody binding. While serines and prolines are often 200 interchangeable amino acids due to their similarity in size, we find that mutation of 201 serine to proline in a protein loop can induce a major conformational change. 202
Proline does not follow the typical Ramachandran plot, due to its cyclic side chain 203 that limits motion in its ψ and φ angles, reducing flexibility to the polypeptide 204 backbone. Because loop structures are often associated with antigenic epitopes, it is 205 possible that viruses mutate amino acids in antigenic loops to prolines to evade 206 binding by some antibodies. Indeed, serine codons, as well as threonine, alanine, 207 leucine, histidine, glutamine, and arginine codons, are most susceptible of becoming 208 a proline codon, since in these cases it requires only a single nucleotide mutation. 209 210 11 One might initially conclude from these studies that vaccines strain antigens 211 with serines in antigenic loops should not be chosen because they are at risk for 212 antibody escape, however we would actually argue the opposite. Specifically, we 213 propose that antigens with serines in antigenic loops should be chosen for vaccine 214 strains because they would elicit more diverse polyclonal antibodies against the 215 diverse conformations in the loop, including conformations observed upon mutation 216 to proline. Indeed, our structures reveal that, with a serine, the loop will sometimes 217 adopt the conformation that is restrained by a proline mutation. In support of this 218 concept, we show that recombinant Spike-2-CDC-Spain, which has a serine in loop 1, 219 elicits antibodies that neutralize all four HAstV-2 strains with prolines in loop 1. 220
Notably, we show that recombinant HAstV capsid spike is immunogenic and 221 elicits neutralizing antibodies. These findings demonstrate the high potential to 222 develop a subunit vaccine to prevent HAstV diarrheal disease. In addition, the 223 affordable, simple, and scalable strategy of producing large amounts of recombinant 224
HAstV capsid spike in E. coli hints at the feasibility of global vaccination. Of course, 225 future studies will be required to determine if a vaccine comprised of capsid spikes 226 from multiple serotypes is required to elicit a broadly protective polyclonal 227 antibody response. 228
229
METHODS 230
Cells, viruses, and reagents. C2Bbe1 cells (ATCC), derived from the human colon 231 adenocarcinoma Caco-2 cell line, were propagated in a 10% CO2 atmosphere at 37°C 232 in Dulbecco´s modified Eagle´s medium-High Glucose (DMEM-HG) (Sigma), 233 supplemented with non-essential amino acids (Gibco) and 15% fetal bovine serum 234 (FBS)(Cansera). HAstV-2 strain Oxford (HAstV-2-Oxford) was obtained from J.B. 235 Kurtz (Dept. of Virology, John Radcliffe Hospital, Oxford, UK) . HAstV-2 strains RIVMa, 236
RIVMb, and RIVMc were obtained from S. Guix (Dept. Microbiologia, Facultat de 237 Biologia, Universitat de Barcelona). All viral strains were activated and grown as 238 described (27), except that 200 ug/ml of trypsin was used to active the virus 239 infectivity. Anti-Spike-2-CDC-Spain polyclonal sera was generated by immunization 240 of mice with recombinant HAstV-2-CDC-Spain capsid spike (see below). For this, 241 female BALB/c mice (8 weeks old) were immunized intraperitoneally with 50 ug of 242 recombinant HAstV capsid spike at 2-week intervals (four times total). The first 243 immunization was done in Freund's complete adjuvant, the second and third with 244 incomplete Freund's adjuvant, and the fourth with no adjuvant. Four days after the 245 fourth immunization the mice were bled to death. Anti-Core-1 polyclonal sera used 246 to detect HAstV infectivity in C2Bbe1 cells was generated by immunization of New 247
Zealand rabbits with recombinant HAstV-1 capsid core (amino acids 80-429) (20) . 248
The generation of polyclonal antibodies to Spike-2-CDC-Spain and to Core-1 was 249 approved by the Bioethics Committee of the Institute of Biotechnology UNAM (# 250 296). 251 252 Neutralization assays. The indicated concentration of antibody or scFv was pre-253 incubated with an m.o.i. of 0.002 of the indicated HAstV-2 strain for 1 h at room 254 temperature. The virus-antibody mix was then added to confluent monolayers 255 C2Bbe1 cells grown in 96 multi-well plates, and incubated for 1 h at 37°C. After this 256 13 time the cells were washed three times with PBS and the infection was left to 257 proceed for 18 h at 37°C. Infected cells were detected by an immunoperoxidase 258 focus-forming assay, as described (28) were incubated overnight at room temperature in 96-well ELISA microtiter plates. 300
Plates were then washed three times with PBS containing 0.05% Tween 20 (PBST). 301 Wells were blocked by adding 150 µL of 5% BSA in PBS and incubating at room 302 temperature for 1 hr followed by three PBST washes. Antibody samples mAb PL-2 303 or scFv PL-2 were diluted to 5 µg/mL with 1% BSA in PBS, and serially diluted 1:3 304 with 1% BSA in PBS. Wells were incubated with 150 µL antibody for 1 hr at room 305 temperature and the plates were washed three times with PBST. For ELISAs where 306 the primary antibody was mAb PL-2, plates were incubated for 1 hr at room 307 temperature with 150 µL HRP-conjugated, secondary goat anti-mouse IgG antibody 308 diluted 1:5,000 in 1% BSA in PBS. For ELISAs where the primary antibody was scFv 309 PL-2, plates were incubated for 1 hr at room temperature with 150 µL HRP-310 conjugated Strep-Tactin protein, diluted 1:5,000 in 1% BSA in PBS. Plates were 311 washed three times with PBST and developed by adding peroxidase substrate o-312 phenylenediamine dihydrochloride (OPD) in 0.05 M phosphate-citrate buffer, pH 5.0 313 and 1.5% hydrogen peroxide for 10 min at room temperature. The reactions were 314 stopped by incubation with 2N sulfuric acid for 10 min at room temperature, and 315 the absorbance was measured at 490 nm. 316 317 Structure determination of Spike-2-Oxford. Purified Spike-2-Oxford in PBS was 318 concentrated to 28.3 mg/mL. Crystals were grown by hanging drop vapor diffusion 319 at 22°C with a well solution of 20 % PEG 3350, 0.2 M magnesium acetate, and 0.1 320 HEPES buffer, pH 7.5. Crystals were transferred into a cryoprotectant solution of 321 25% PEG 3350, 25% glycerol, 0.2M magnesium acetate, 0.1M HEPES, pH 7.5, and 322 flash frozen in liquid nitrogen. Diffraction data were collected at cryogenic 323 temperature at the Advanced Photon Source on beamline 23-ID-B using a 324 16 wavelength of 1.033 Å. Diffraction data from a single crystal were processed with 325 iMosflm(29) and Scala(30)( Table 1 ). The Spike-2-Oxford structure was solved by 326 molecular replacement, using the HAstV-2-CDC-Spain capsid spike (PDB ID 327 5KOU)(22) and the program PHASER(31). The Spike-2-Oxford structure was refined 328 and manually rebuilt using PHENIX (32) and Coot(33), respectively. The final Spike-329 2-Oxford structure had two dimers in the asymmetric unit of the crystal. We thank Rafaela Espinosa for the production of hyperimmune sera to HAstV spike 336 and core domains, and to Marco A. Espinoza for sequencing the capsid regions of 337
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